The treatment was approved by China’s National Medical Products Administration (NMPA) and is China's first, and the world’s ...

Diana Portillo said she faced discrimination while working at the fast-food restaurant in Washington, D.C. Now she helps other trans women in their struggles.

As China's first and the world's second approved IGF-1R antibody drug, SYCUME® has ended a 70-year drought of no new treatment option for TED in China. This groundbreaking therapy will redefine ...

Moors & Cabot Inc. boosted its stake in shares of iShares Global Infrastructure ETF (NASDAQ:IGF – Free Report) by 12.9% during the 4th quarter, according to its most recent Form 13F filing with the ...

ASGI ETF's 13.47% yield is sustainable. Explore risks, transparency, and better ETF alternatives like PAVE for stable ...

Innovent Biologics (HKEX: 01801) has gained approval in China for Sycume (teprotumumab), the country’s first IGF-1R antibody ...

The Internet Governance Forum (IGF)'s support to journalists from the Global South is an initiative to promote insightful, ...

An announcement from Innovent Biologics ( ($HK:1801) ) is now available. Innovent Biologics has announced the approval of SYCUME®, China’s first ...

Innovent Biologics’ Sycume receives China NMPA approval for treatment of thyroid eye disease: San Francisco Monday, March 17, 2025, 16:00 Hrs [IST] Innovent Biologics, Inc, a wo ...

SAN FRANCISCO and SUZHOU, China, March 14, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutic ...

("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and ...